

WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising an effective amount of an antibody comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell,

wherein the first antigen-binding domain comprises:

(a) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

(b) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98,

99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

(c) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101; or

(d) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53,

57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98; and

wherein:

(i) the dissociation rate of the first antigen-binding domain at a pH of 4.0 to 6.5 is faster than the dissociation rate at a pH of 7.0 to 8.0; or

(ii) the dissociation constant (K_D) of the first antigen-binding domain at a pH of 4.0 to 6.5 is greater than the K_D at a pH of 7.0 to 8.0.

2. The pharmaceutical composition of claim 1, wherein the antibody is degraded in the target mammalian cell following internalization of the antibody by the target mammalian cell.

3. The pharmaceutical composition of claim 1 or 2, wherein the antibody further comprises a conjugated toxin, radioisotope, drug, or small molecule.

4. A pharmaceutical composition comprising an effective amount of an antibody comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell; and

a conjugated toxin, radioisotope, drug, or small molecule,

wherein the first antigen-binding domain comprises:

(a) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

(b) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

(c) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101; or

(d) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98; and

wherein:

(i) the dissociation rate of the first antigen-binding domain at a pH of 4.0 to 6.5 is faster than the dissociation rate at a pH of 7.0 to 8.0; or

the dissociation constant (K_D) of the first antigen-binding domain at a pH of 4.0 to 6.5 is greater than the K_D at a pH of 7.0 to 8.0; and

(ii) the composition provides for one or more of:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control antibody;

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control antibody; and

an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control antibody.

5. The pharmaceutical composition of claim 1 or 4, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a light chain variable domain of SEQ ID NO: 2, SEQ ID NO: 52, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140, and/or

a heavy chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 94, or SEQ ID NO: 111,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain of SEQ ID NO: 1; (ii) a light chain variable domain of SEQ ID NO: 2 and heavy chain variable domain that is not one of SEQ ID NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140;

(b) a light chain variable domain of SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300, or SEQ ID NO: 301, and/or

a heavy chain variable domain of SEQ ID NO: 146, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 187, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO: 220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, or SEQ ID NO: 236,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain of SEQ ID NO: 146; (ii) a light chain variable domain of SEQ ID NO: 147 and heavy chain variable domain that is not one of SEQ ID NOs: 159, 164-168, 170, 171, 173, 182-184, 187, 217-228, and 230-236; or (iii) a heavy chain variable domain of SEQ ID NO: 146 and a light chain variable domain that is not one of SEQ ID NOs: 190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300 and 301;

(c) a light chain variable domain of SEQ ID NO: 305, SEQ ID NO: 352, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 360, SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 457, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID NO: 479, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID NO: 496, or SEQ ID NO: 499, and/or

a heavy chain variable domain of SEQ ID NO: 304, SEQ ID NO: 313, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO:

390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, or SEQ ID NO: 400,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain of SEQ ID NO: 304; (ii) a light chain variable domain of SEQ ID NO: 305 and heavy chain variable domain that is not one of SEQ ID NOs: 313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393, and 395-400; or (iii) a heavy chain variable domain of SEQ ID NO: 304 and a light chain variable domain that is not one of SEQ ID NOs: 352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496, and 499; and

(d) a light chain variable domain of SEQ ID NO: 503, SEQ ID NO: 550, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 562, SEQ ID NO: 565, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704, SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO: 708, SEQ ID NO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 712, SEQ ID NO: 713, or SEQ ID NO: 732, and/or

a heavy chain variable domain of SEQ ID NO: 502, SEQ ID NO: 511, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 527, SEQ ID NO: 529, SEQ ID NO: 538, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 587, SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 606, SEQ ID NO: 621, SEQ ID NO: 659, or SEQ ID NO: 676,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain of SEQ ID NO: 502; or (ii) a light chain variable domain of SEQ ID NO: 503 and heavy chain variable domain that is not one of SEQ ID NOs: 511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659, and 676; or (iii) a heavy chain variable domain of SEQ ID NO: 502 and light

chain variable domain that is not one of SEQ ID NOs: 550, 554, 556-560, 562, 565, 569, 570-576, 697-713, and 732.

6. The pharmaceutical composition of any one of claims 1-5, wherein the composition provides for:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control antibody; and/or

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control antibody.

7. The pharmaceutical composition of any one of claims 1-6, wherein the composition provides for an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control antibody.

8. The pharmaceutical composition of any one of claims 1-7, wherein the composition:

results in a less of a reduction in the level of MET presented on the surface of the target mammalian cell as compared to a composition comprising the same amount of a control antibody; or

does not result in a detectable reduction in the level of MET presented on the surface of the target mammalian cell.

9. The pharmaceutical composition of any one of claims 1-8, wherein the target mammalian cell is a cancer cell.

10. The pharmaceutical composition of any one of claims 1-9, wherein the antibody is cytotoxic or cytostatic to the target mammalian cell.

11. The pharmaceutical composition of any one of claims 1-10, wherein the antibody is:

cross-reactive with a non-human primate MET and human MET; or

cross-reactive with a non-human primate MET, a human MET, and one or both of rat MET and a mouse MET.

12. The pharmaceutical composition of any one of claims 1-11, wherein the antibody further comprises a second antigen-binding domain.

13. An antibody comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell,

wherein the antigen-binding domain comprises:

(a) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

(b) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98,

99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

(c) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101; or

(d) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53,

57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98; and

wherein:

(i) the dissociation rate of the first antigen-binding domain at a pH of 4.0 to 6.5 is faster than the dissociation rate at a pH of 7.0 to 8.0; or

(ii) the dissociation constant (KD) of the first antigen-binding domain at a pH of 4.0 to 6.5 is greater than the KD at a pH of 7.0 to 8.0.

14. The antibody of claim 13, wherein the antibody is degraded in the target mammalian cell following internalization of the antibody by the target mammalian cell.

15. The antibody of claim 13 or 14, wherein the antibody further comprises a conjugated toxin, radioisotope, drug, or small molecule.

16. An antibody comprising:

a first antigen-binding domain that is capable of specifically binding MET or an epitope of MET presented on the surface of a target mammalian cell; and

a conjugated toxin, radioisotope, drug, or small molecule,

wherein the first antigen-binding comprises:

(a) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102, 103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 1 selected from the group consisting of: 26, 27, 28, 29, 32, 97, 98, 99, 100, 101, 102,

103, and 107, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 1 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 2, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 2 selected from the group consisting of: 25, 28, 29, 30, 31, 32, 34, 35, 36, 37, 54, 55, 59, 60, 95, 99, and 101;

(b) a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 146 selected from the group consisting of: 31, 50, 51, 52, 53, 54, 56, 57, 59, 98, 99, 100, and 103, and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147; or

a heavy chain variable domain comprising the heavy chain CDRs in SEQ ID NO: 146 and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 147, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 147 selected from the group consisting of: 25, 26, 29, 32, 33, 51, 91, 92, 95, 96, and 97;

(c) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 304 selected from the group consisting of: 27, 34, 35, 50, 51, 52, 54, 55, 56, 57,

58, 59, 60, 61, 62, 63, 64, 65, 98, 99, 103, and 105; and a light chain variable domain comprising the light chain CDRs in SEQ ID NO: 305; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 304 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 305, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 305 selected from the group consisting of: 26, 30, 31, 34, 36, 54, 56, 57, 60, 93, 95, 99, and 101; or

(d) a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98;

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502, wherein the heavy chain variable domain includes a histidine at one or more positions in SEQ ID NO: 502 selected from the group consisting of: 27, 29, 30, 32, 33, 34, 50, 51, 52, 53, 57, 59, 98, 100, 101, 102, 103, 106, and 107, and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503; or

a heavy chain variable domain comprising the heavy chain CDRs of SEQ ID NO: 502 and a light chain variable domain comprising the light chain CDRs of SEQ ID NO: 503, wherein the light chain variable domain includes a histidine at one or more positions in SEQ ID NO: 503 selected from the group consisting of: 25, 29, 31, 32, 33, 34, 35, 52, 55, 91, 92, 93, 94, 95, 96, 97, and 98; and

wherein:

(i) the dissociation rate of the first antigen-binding domain at a pH of 4.0 to 6.5 is faster than the dissociation rate at a pH of 7.0 to 8.0; or

the dissociation constant (K_D) of the first antigen-binding domain at a pH of 4.0 to 6.5 is greater than the K_D at a pH of 7.0 to 8.0; and

(ii) the composition provides for one or more of:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control antibody;

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control antibody; and

an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control antibody.

17. The antibody of claim 13 or 16, wherein the first antigen-binding domain comprises one of (a) through (d):

(a) a light chain variable domain of SEQ ID NO: 2, SEQ ID NO: 52, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 67, SEQ ID NO: 71, SEQ ID NO: 72, SEQ ID NO: 75, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 131, SEQ ID NO: 132, SEQ ID NO: 133, SEQ ID NO: 134, SEQ ID NO: 135, SEQ ID NO: 136, SEQ ID NO: 137, SEQ ID NO: 138, SEQ ID NO: 139, or SEQ ID NO: 140, and/or

a heavy chain variable domain of SEQ ID NO: 1, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 19, SEQ ID NO: 40, SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 50, SEQ ID NO: 82, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 90, SEQ ID NO: 94, or SEQ ID NO: 111,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 2 and a heavy chain variable domain of SEQ ID NO: 1; (ii) a light chain variable domain of SEQ ID NO: 2 and heavy chain variable domain that is not one of SEQ ID NOs: 13-16, 19, 40-46, 50, 82-84, 86, 87, 89, 90, 94, and 111; or (iii) a heavy chain variable domain of SEQ ID NO: 1 and a light chain variable domain that is not one of SEQ ID NOs: 52, 55-59, 61-67, 71, 72, 75, 79, 81, and 131-140;

(b) a light chain variable domain of SEQ ID NO: 147, SEQ ID NO: 190, SEQ ID NO: 191, SEQ ID NO: 194, SEQ ID NO: 197, SEQ ID NO: 198, SEQ ID NO: 200, SEQ ID NO: 201, SEQ ID NO: 209, SEQ ID NO: 210, SEQ ID NO: 213, SEQ ID NO: 214, SEQ ID NO: 215, SEQ ID NO: 284, SEQ ID NO: 285, SEQ ID NO: 286, SEQ ID NO: 287, SEQ ID NO: 288, SEQ ID NO: 289, SEQ ID NO: 290, SEQ ID NO: 291, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 296, SEQ ID NO: 297, SEQ ID NO: 298, SEQ ID NO: 300, or SEQ ID NO: 301, and/or

a heavy chain variable domain of SEQ ID NO: 146, SEQ ID NO: 159, SEQ ID NO: 164, SEQ ID NO: 165, SEQ ID NO: 166, SEQ ID NO: 167, SEQ ID NO: 168, SEQ ID NO: 170, SEQ ID NO: 171, SEQ ID NO: 173, SEQ ID NO: 182, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 187, SEQ ID NO: 217, SEQ ID NO: 218, SEQ ID NO: 219, SEQ ID NO:

220, SEQ ID NO: 221, SEQ ID NO: 222, SEQ ID NO: 223, SEQ ID NO: 224, SEQ ID NO: 225, SEQ ID NO: 226, SEQ ID NO: 227, SEQ ID NO: 228, SEQ ID NO: 230, SEQ ID NO: 231, SEQ ID NO: 232, SEQ ID NO: 233, SEQ ID NO: 234, SEQ ID NO: 235, or SEQ ID NO: 236,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 147 and a heavy chain variable domain of SEQ ID NO: 146; (ii) a light chain variable domain of SEQ ID NO: 147 and heavy chain variable domain that is not one of SEQ ID NOs: 159, 164-168, 170, 171, 173, 182-184, 187, 217-228, and 230-236; or (iii) a heavy chain variable domain of SEQ ID NO: 146 and a light chain variable domain that is not one of SEQ ID NOs: 190, 191, 194, 197, 198, 200, 201, 209, 210, 213-215, 284-298, 300 and 301;

(c) a light chain variable domain of SEQ ID NO: 305, SEQ ID NO: 352, SEQ ID NO: 356, SEQ ID NO: 357, SEQ ID NO: 360, SEQ ID NO: 362, SEQ ID NO: 364, SEQ ID NO: 365, SEQ ID NO: 367, SEQ ID NO: 368, SEQ ID NO: 371, SEQ ID NO: 372, SEQ ID NO: 374, SEQ ID NO: 378, SEQ ID NO: 380, SEQ ID NO: 428, SEQ ID NO: 429, SEQ ID NO: 430, SEQ ID NO: 431, SEQ ID NO: 432, SEQ ID NO: 433, SEQ ID NO: 434, SEQ ID NO: 435, SEQ ID NO: 436, SEQ ID NO: 437, SEQ ID NO: 438, SEQ ID NO: 439, SEQ ID NO: 440, SEQ ID NO: 441, SEQ ID NO: 442, SEQ ID NO: 443, SEQ ID NO: 444, SEQ ID NO: 445, SEQ ID NO: 446, SEQ ID NO: 450, SEQ ID NO: 451, SEQ ID NO: 453, SEQ ID NO: 457, SEQ ID NO: 462, SEQ ID NO: 463, SEQ ID NO: 465, SEQ ID NO: 470, SEQ ID NO: 472, SEQ ID NO: 473, SEQ ID NO: 474, SEQ ID NO: 476, SEQ ID NO: 479, SEQ ID NO: 482, SEQ ID NO: 483, SEQ ID NO: 485, SEQ ID NO: 490, SEQ ID NO: 492, SEQ ID NO: 494, SEQ ID NO: 496, or SEQ ID NO: 499, and/or

a heavy chain variable domain of SEQ ID NO: 304, SEQ ID NO: 313, SEQ ID NO: 320, SEQ ID NO: 321, SEQ ID NO: 322, SEQ ID NO: 323, SEQ ID NO: 324, SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 328, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 331, SEQ ID NO: 332, SEQ ID NO: 333, SEQ ID NO: 334, SEQ ID NO: 335, SEQ ID NO: 336, SEQ ID NO: 337, SEQ ID NO: 340, SEQ ID NO: 341, SEQ ID NO: 345, SEQ ID NO: 347, SEQ ID NO: 381, SEQ ID NO: 382, SEQ ID NO: 383, SEQ ID NO: 384, SEQ ID NO: 385, SEQ ID NO: 386, SEQ ID NO: 387, SEQ ID NO: 388, SEQ ID NO: 389, SEQ ID NO: 390, SEQ ID NO: 392, SEQ ID NO: 393, SEQ ID NO: 395, SEQ ID NO: 396, SEQ ID NO: 397, SEQ ID NO: 398, SEQ ID NO: 399, or SEQ ID NO: 400,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 305 and a heavy chain variable domain of SEQ ID NO: 304; (ii) a

light chain variable domain of SEQ ID NO: 305 and heavy chain variable domain that is not one of SEQ ID NOs: 313, 320-324, 326-337, 340, 341, 345, 347, 381-390, 392, 393, and 395-400; or (iii) a heavy chain variable domain of SEQ ID NO: 304 and a light chain variable domain that is not one of SEQ ID NOs: 352, 356, 357, 360, 362, 364, 365, 367, 368, 371, 372, 374, 378, 380, 428-446, 450, 451, 453, 457, 462, 463, 465, 470, 472-474, 476, 479, 482, 483, 485, 490, 492, 494, 496, and 499; and

(d) a light chain variable domain of SEQ ID NO: 503, SEQ ID NO: 550, SEQ ID NO: 554, SEQ ID NO: 556, SEQ ID NO: 557, SEQ ID NO: 558, SEQ ID NO: 559, SEQ ID NO: 560, SEQ ID NO: 562, SEQ ID NO: 565, SEQ ID NO: 569, SEQ ID NO: 570, SEQ ID NO: 571, SEQ ID NO: 572, SEQ ID NO: 573, SEQ ID NO: 574, SEQ ID NO: 575, SEQ ID NO: 576, SEQ ID NO: 697, SEQ ID NO: 698, SEQ ID NO: 699, SEQ ID NO: 700, SEQ ID NO: 701, SEQ ID NO: 702, SEQ ID NO: 703, SEQ ID NO: 704, SEQ ID NO: 705, SEQ ID NO: 706, SEQ ID NO: 707, SEQ ID NO: 708, SEQ ID NO: 709, SEQ ID NO: 710, SEQ ID NO: 711, SEQ ID NO: 712, SEQ ID NO: 713, or SEQ ID NO: 732, and/or

a heavy chain variable domain of SEQ ID NO: 502, SEQ ID NO: 511, SEQ ID NO: 513, SEQ ID NO: 514, SEQ ID NO: 516, SEQ ID NO: 517, SEQ ID NO: 518, SEQ ID NO: 519, SEQ ID NO: 520, SEQ ID NO: 521, SEQ ID NO: 522, SEQ ID NO: 523, SEQ ID NO: 527, SEQ ID NO: 529, SEQ ID NO: 538, SEQ ID NO: 540, SEQ ID NO: 541, SEQ ID NO: 542, SEQ ID NO: 543, SEQ ID NO: 546, SEQ ID NO: 547, SEQ ID NO: 578, SEQ ID NO: 579, SEQ ID NO: 580, SEQ ID NO: 581, SEQ ID NO: 582, SEQ ID NO: 583, SEQ ID NO: 584, SEQ ID NO: 585, SEQ ID NO: 586, SEQ ID NO: 587, SEQ ID NO: 588, SEQ ID NO: 589, SEQ ID NO: 590, SEQ ID NO: 591, SEQ ID NO: 592, SEQ ID NO: 593, SEQ ID NO: 594, SEQ ID NO: 595, SEQ ID NO: 596, SEQ ID NO: 597, SEQ ID NO: 606, SEQ ID NO: 621, SEQ ID NO: 659, or SEQ ID NO: 676,

wherein the first antigen-binding domain does not comprise (i) a light chain variable domain of SEQ ID NO: 503 and a heavy chain variable domain of SEQ ID NO: 502; or (ii) a light chain variable domain of SEQ ID NO: 503 and heavy chain variable domain that is not one of SEQ ID NOs: 511, 513, 514, 516-523, 527, 529, 538, 540-543, 546, 547, 578-597, 606, 621, 659, and 676; or (iii) a heavy chain variable domain of SEQ ID NO: 502 and light chain variable domain that is not one of SEQ ID NOs: 550, 554, 556-560, 562, 565, 569, 570-576, 697-713, and 732.

18. The antibody of any one of claims 13-17, wherein a composition comprising the antibody provides for:

an increase in toxin liberation in the target mammalian cell as compared to a composition comprising the same amount of a control antibody; and/or

an increase in target mammalian cell killing as compared to a composition comprising the same amount of a control antibody.

19. The antibody of any one of claims 13-18, wherein a composition comprising the antibody provides for an increase in endolysosomal delivery in the target mammalian cell as compared to a composition comprising the same amount of a control antibody.

20. The antibody of any one of claims 13-19, wherein a composition comprising the antibody:

results in a less of a reduction in the level of MET presented on the surface of the target mammalian cell as compared to a composition comprising the same amount of a control antibody; or

does not result in a detectable reduction in the level of MET presented on the surface of the target mammalian cell.

21. The antibody of any one of claims 13-20, wherein the target mammalian cell is a cancer cell.

22. The antibody of any one of claims 13-21, wherein the antibody is cytotoxic or cytostatic to the target mammalian cell.

23. The antibody of any one of claims 13-22, wherein the antibody is:
cross-reactive with a non-human primate MET and human MET; or
cross-reactive with a non-human primate MET, a human MET, and one or both of rat MET and a mouse MET.

24. The antibody of any one of claims 13-23, wherein the antibody further comprises a second antigen-binding domain.

25. A kit comprising at least one dose of the pharmaceutical composition of any one of claims 1-12 or the antibody of any one of claims 13-24.

26. A pharmaceutical composition of any one of claims 1-12 or an antibody of any one of claims 13-24 for use in the treatment of a cancer in a subject characterized by having a population of cancer cells that have MET or an epitope of MET presented on their surface.

27. A pharmaceutical composition of any one of claims 1-12 or an antibody of any one of claims 13-24 for use in reducing the volume of a tumor in a subject, wherein the tumor is characterized by having a population of cancer cells that have MET or an epitope of MET presented on their surface.

28. A pharmaceutical composition of any one of claims 1-12 or an antibody of any one of claims 13-24 for use in inducing cell death in a cancer cell in a subject, wherein the cancer cell has MET or an epitope of MET presented on its surface.

29. A pharmaceutical composition of any one of claims 1-12 or an antibody of any one of claims 13-24 for use in decreasing the risk of developing a metastasis or decreasing the risk of developing an additional metastasis in a subject having a cancer, wherein the cancer is characterized by having a population of cancer cells that have MET or an epitope of MET presented on their surface.